Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory Diseases
Search
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Rabies wildlife 5 things to know
Rabies in wildlife - 5 things to know to protect yourself and your pet
How do I treat mild to moderate renal impairment with Pradaxa®
.
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
COVID-19 Q&A for people with chronic respiratory conditions
COVID-19 Q&A for people with chronic respiratory conditions
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19